H

Harry P. Erba

Michigan Center for Translational Pathology

ORCID: 0000-0003-1093-2189

567 papers and 19.4k citations.

PubIndex Score88Top 12% · seniorHow it's scored

567Publications

19.4kTotal Citations

First publication: 1980First senior author: 2009

Top publicationsby citations

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Hagop M. Kantarjian, Will Donnellan et al.|New England Journal of Medicine|2018

Cited by 1.4k

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Martin S. Tallman, Xin V. Wang et al.|New England Journal of Medicine|2019

Cited by 735

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Frederick R. Appelbaum, Kenneth J. Kopecky et al.|Blood|2013

Cited by 632

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

Mark R. Litzow, Martin S. Tallman, Zhuoxin Sun et al.|New England Journal of Medicine|2024

Cited by 213

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Harry P. Erba, Michael Andreeff|Investigational New Drugs|2013

Cited by 72

Indexing the rest of 567 publications…